On August 31, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference (Press release, Infinity Pharmaceuticals, AUG 31, 2022, View Source [SID1234618823]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 Wells Fargo Healthcare Conference
Date: Friday, September 9, 2022
Time: 8:00 a.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: In-person fireside chat and 1-on-1 meetings
Webcast Registration Link

H.C. Wainwright 24th Annual Global Investment Conference
Date: Monday, September 12, 2022
Time: Presentation available at 7:00 a.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: Virtual company presentation and 1-on-1 meetings
Webcast Registration Link

A replay of the presentations will be available in the Investors/Media section of Infinity’s website at www.infi.com for 90 days following the events.